Literature DB >> 2056131

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

R Bataille1, D Chappard, C Marcelli, P Dessauw, P Baldet, J Sany, C Alexandre.   

Abstract

Considering the special relation of human multiple myeloma (MM) to bones, it is of importance to clarify the early steps of bone involvement in this disease. In this work, using bone histomorphometry (including histoenzymologic and kinetic studies for the first time), we have evaluated the bone remodeling (i.e., bone resorption and bone formation rates) of 16 individuals with early MM in comparison with that of 10 with benign monoclonal gammopathy (BMG) and that of 17 patients with previously untreated overt MM. A significantly increased osteoblastic recruitment was observed in the individuals with early MM when compared with those with BMG (P less than 0.01). A significant (P less than 0.01) increased bone resorption (i.e., eroded surfaces, osteoclast numbers and surfaces) was observed from the early stage of MM in comparison with the BMG status where bone resorption remained within the normal range. At the tissue level, there was no difference in terms of bone resorption between early and overt MM. On the other hand, osteoblast activity was significantly reduced in patients with overt MM (P less than 0.05 by comparison with those with early MM). A significant enhancement of osteoblastic recruitment with an increased generation of new osteoclasts is an early critical event in the pathogenesis of human MM. Of particular importance is the early stimulation of osteoblasts, since these cells produce high amounts of IL-6, a potent myeloma cell growth factor and a critical cytokine for the formation of osteoclasts in the bone marrow.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056131      PMCID: PMC296003          DOI: 10.1172/JCI115305

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells.

Authors:  B E Barton; R Mayer
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

2.  Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures.

Authors:  B R MacDonald; G R Mundy; S Clark; E A Wang; T J Kuehl; E R Stanley; G D Roodman
Journal:  J Bone Miner Res       Date:  1986-04       Impact factor: 6.741

Review 3.  Monoclonal gammopathies of undetermined significance.

Authors:  R A Kyle; J A Lust
Journal:  Semin Hematol       Date:  1989-07       Impact factor: 3.851

4.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

Authors:  B Klein; X G Zhang; M Jourdan; J Content; F Houssiau; L Aarden; M Piechaczyk; R Bataille
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

5.  Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma.

Authors:  M Kawano; I Yamamoto; K Iwato; H Tanaka; H Asaoku; O Tanabe; H Ishikawa; M Nobuyoshi; Y Ohmoto; Y Hirai
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

6.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

7.  Evaluation of the osteoclastic population in iliac crest biopsies from 36 normal subjects: a histoenzymologic and histomorphometric study.

Authors:  S Palle; D Chappard; L Vico; G Riffat; C Alexandre
Journal:  J Bone Miner Res       Date:  1989-08       Impact factor: 6.741

8.  Production of interleukin-1 by bone marrow myeloma cells.

Authors:  F Cozzolino; M Torcia; D Aldinucci; A Rubartelli; A Miliani; A R Shaw; P M Lansdorp; R Di Guglielmo
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

9.  Generation of osteoclasts from isolated hematopoietic progenitor cells.

Authors:  N Kurihara; T Suda; Y Miura; H Nakauchi; H Kodama; K Hiura; Y Hakeda; M Kumegawa
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

10.  Numbers of host "helper" T cells and proliferating cells predict survival in diffuse small-cell lymphomas.

Authors:  L J Medeiros; L J Picker; A B Gelb; J G Strickler; S W Brain; L M Weiss; S J Horning; R A Warnke
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

View more
  50 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

2.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 3.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Authors:  Jerome Moreaux; Dirk Hose; Alboukadel Kassambara; Thierry Reme; Philippe Moine; Guilhem Requirand; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

5.  A physical mechanism for coupling bone resorption and formation in adult human bone.

Authors:  Thomas Levin Andersen; Teis Esben Sondergaard; Katarzyna Ewa Skorzynska; Frederik Dagnaes-Hansen; Trine Lindhardt Plesner; Ellen Margrethe Hauge; Torben Plesner; Jean-Marie Delaisse
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

6.  Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.

Authors:  Syed J Mehdi; Sarah K Johnson; Joshua Epstein; Maurizio Zangari; Pingping Qu; Antje Hoering; Frits van Rhee; Carolina Schinke; Sharmilan Thanendrarajan; Bart Barlogie; Faith E Davies; Gareth J Morgan; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

7.  Role of decorin in the antimyeloma effects of osteoblasts.

Authors:  Xin Li; Angela Pennisi; Shmuel Yaccoby
Journal:  Blood       Date:  2008-04-24       Impact factor: 22.113

8.  Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Sharmin Khan; Shmuel Yaccoby
Journal:  Cancer Lett       Date:  2009-05-15       Impact factor: 8.679

9.  The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Maurizio Zangari; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2009-01       Impact factor: 10.047

10.  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.

Authors:  Ya-Wei Qiang; John D Shaughnessy; Shmuel Yaccoby
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.